Introduction
============

Colorectal cancer (CRC) is one of the most common cancers, responsible for 715,000 worldwide deaths in 2010 [@B1]. It is the second most common cause of cancer death in the USA [@B2]. In China, colorectal cancer is the fourth most common cause of death and the fifth most common cancer type [@B3]. In spite of the development of novel treatment options and early screening, the prognosis of CRC patients has not improved markedly. Furthermore, the incidence of CRC in China has been rising rapidly in recent years [@B4]. Hence, novel biomarkers with clinical value are urgently needed to improve the compliance rate.

MicroRNAs are small non-coding RNAs containing 18-22 nucleotides which play a role in RNA silencing and post-transcriptional regulation of targeted genes. The miR-200 family contains miR-141, miR-200a, miR-200b, miR-200c and miR-429. Increasing evidence suggests miR-200 microRNAs played a role in cancer metastasis [@B5]-[@B14]. In CRC, miR-200 microRNAs were reported to influence the prognosis of cancer patients by regulating genes related to the epithelial to mesenchymal transition [@B10], [@B15]-[@B19]. Previous studies have shown that the high expression of miR-200 microRNAs has an impact on the overall- and Relapse-free Survival of CRC patients. However, the results were inconsistent. This paper aims to investigate the prognostic value of the MiR-200 family in patients with colorectal cancer via a meta-analysis of available literature.

Materials and Methods
=====================

Literature search
-----------------

A comprehensive literature search was conducted in PMC (PubMed Central), PubMed, Web of Science, Embase, and Cochrane library, with a cut-off date of May 11, 2018, to obtain potentially eligible studies. The keywords for the search were ("miR-141" OR "miR-200a" OR "miR-200b" OR "miR-200c" OR "miR-429") AND ("colorectal cancer" OR "Colorectal Tumor" OR "Colorectal Neoplasm" OR "Colorectal Carcinoma") AND ("prognosis" OR "survival"). Additionally, other relevant articles were also obtained by manually screening the reference lists.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria for the articles were as follows: (1) the association between miR-200 family expression and overall survival (OS)/Relapse-free Survival (RFS) was investigated in patients with colorectal cancer; (2) the studies provided hazard ratios (HRs) and their 95% CIs of OS or RFS; (3) the patients were divided into low- and high expression groups according to the expression level of miR-200 microRNAs. Exclusion criteria for the articles were as follows: (1) duplicate publications; (2) studies with unusable data; and (3) reviews, letters, case reports and expert opinions.

Data extraction and quality assessment
--------------------------------------

Two investigators (H-W and R-S) collected the data and information from all included studies. The following information was extracted from each study: first author name, publication year, total number of patients, outcome measures, the criteria for high miR-200 microRNA expression, determination method, hazard ratios (HRs) and corresponding 95% CIs. For all included studies, the results of multivariate analysis were only selected because of its increased precision for interpreting confounding factors. If a study provided the results of both multivariate and univariate outcomes, we chose the former. If a study only provided Kaplan-Meier survival curves, we extracted the corresponding survival data by using Engauge Digitizer V4.1 [@B20]. In the event of a disagreement, a third investigator (W-W) was consulted to reach a consensus. The quality of all included studies was assessed by using the Newcastle-Ottawa Scale (NOS) (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). The NOS scores ranged from 0 to 9 and studies with NOS scores ≥ 6 were considered to be of high quality. The quality of all included studies varied from 7 to 9, with a mean value of 7.77 (Table [2](#T2){ref-type="table"}).

Statistical methods
-------------------

The meta-analysis was conducted by using Stata SE12.0 (Stata Corp, College Station, TX) and R software 3.5.3 (Microsoft Revolution Analytics). The heterogeneity across studies was assessed by using the Chi square-based Q test and I^2^ statistics [@B21]. A *P*-value of less than 0.05 for the Q test or an I^2^ value of more than 50 % was considered to indicate a significant difference. If the heterogeneity across studies was small (P~h~ \> 0.05, I^2^ \< 50%), the fixed effects model was adopted. Otherwise, the random effects model was applied (P~h~ ≤ 0.05, I^2^ ≥ 50%). Potential publication bias was calculated using Begg\'s test and Egger\'s test [@B22]. A sensitivity analysis was also conducted to evaluate the stability of the results. Differences with *P*-values of less than 0.05 were considered statistically significant.

Results
=======

Study characteristics
---------------------

The detailed process of literature retrieval is shown in Figure [1](#F1){ref-type="fig"}. A total of 1882 cancer patients in 9 studies [@B23]-[@B31] were ultimately included in the meta-analysis. The mean sample size was 209 patients (from 78 to 543). The included studies were from America, Asia and Europe (Table [1](#T1){ref-type="table"}).

The expression of miR-200 microRNAs and overall survival
--------------------------------------------------------

The forest plots for the association between miR-200 expression and overall survival of patients with colorectal cancer are shown in Figure [2](#F2){ref-type="fig"}. Overall, The HRs of the high miR-200 microRNAs expression group versus the low miR-200 microRNAs expression group was 1.18 (95% CI 0.98-1.43, Figure [2](#F2){ref-type="fig"}A). Stratified analysis by sample types showed a significant association between enhanced expression of miR-200c in plasma and poor OS (HR=1.23, 95% CI 1.08-1.41, Figure [2](#F2){ref-type="fig"}B). Moreover, a significant association was found between higher expression of the miR-200 family and poorer OS in the Asian population (HR=2.06, 95% CI 1.58-2.68), compared with the European population (HR=1.11, 95% CI 0.99-1.26, Figure [2](#F2){ref-type="fig"}B) (Table [3](#T3){ref-type="table"}).

The expression of miR-200 microRNAs and Relapse-free Survival
-------------------------------------------------------------

Only three studies with a total of 1098 patients contained data on Relapse-free Survival (RFS). No obvious statistical heterogeneity was observed among the included studies (I^2^ = 0 %; P~h~ = 0.446). The fixed-effects model was adopted to assess the pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). The overall result demonstrated a strong association between high expression levels of miR-200 microRNAs and poor RFS (HR=1.13, 95% CI 1.04-1.23, Figure [3](#F3){ref-type="fig"}A). Stratified analysis by country revealed a poorer RFS in patients with high expression levels of miR-200 microRNAs from Asia. Furthermore, stratified analysis by sample types found a significant association between higher expression of the miR-200 family and poor RFS in plasma (HR= 1.12, 95% CI 1.03-1.21, Figure [3](#F3){ref-type="fig"}B) (Table [3](#T3){ref-type="table"}).

Sensitivity analysis
--------------------

To investigate the correlation between the expression of miR-200 microRNAs and OS, sensitivity analysis was conducted by sequentially omitting each study from the pooled analysis, one at a time. The result was not obviously influenced by the exclusion of any study, which underscored the robustness of the results (Figure [4](#F4){ref-type="fig"}).

Publication bias
----------------

For the relationship between miR-200 microRNA expression levels and OS, Begg\'s test and Egger\'s test were applied to test for publication bias. No publication bias was observed in the included studies (Figure [5](#F5){ref-type="fig"}).

Discussion
==========

MiR-200 microRNAs were found to act together with ZEB1 and ZEB2 proteins to regulate the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) in the development of CRC and influence its prognosis[@B15], [@B32]. Some studies showed that high expression of MiR-200 microRNAs was associated with improved OS in CRC patients [@B15], [@B29]. However, other studies demonstrated that the high expression of MiR-200 microRNAs was related to poor OS in comparable patients [@B24]-[@B28]. Although the inconsistent results of these studies have not yet been explained in detail, the discrepancy might partly attributed to the different results of microarray analysis, since these miRNA profiling studies were conducted with different microarray platforms. Furthermore, small differences of experimental design across studies could also affect the observed results. Notably, the insufficient number of tumor samples in the inclusive studies could have led to limited statistical power, diminishing the observed prognostic value of the miR-200 family.

In the current paper, we assessed the relationship between the survival of patients with colorectal cancer and miR-200 expression. The pool analysis showed that higher expression of miR-200 family RNAs was observed to be related to poor RFS in patients with colorectal cancer. Furthermore, the subgroup analysis of sample types found a significant association between higher expression of the miR-200 family in the ser poorer OS and RFS, which implied that the miR-200 family might become an easily detectable biomarker for the evaluation of the prognosis of patients with colorectal cancer.

However, there are some limitations to our meta-analysis. Firstly, the total sample size was relatively small and we failed to detect a relationship between the expression of miR-200 microRNAs and clinicopathological parameters. Secondly, there was significant heterogeneity across studies regarding the association of the miR-200 family with OS. Subgroup analysis demonstrated that the country of origin of the inclusive studies might be the main source of heterogeneity. Thirdly, the number of inclusive studies is small, whose statistical power is still limited. Although the result of publication bias demonstrated that there did not exist publication bias, there may exist publication bias because of limited inclusive studies. Fourthly, there still exists small differences in the role of each member of miR-200 family in colorectal cancer, which may cause also affect the observed results. Fifth, estimating HRs from Kaplan Meier curves can become inaccurate when there are very small differences in overall OS and RFS, which may also have impacted the results of this meta-analysis. Furthermore, the different methods/platforms used for mRNA detection, inconsistent definition of OS/RFS, various sample sources and different types of disease might cause a deviation of the results of this meta-analysis. Finally, this paper did not assess the prognostic value of a combination of miR-200 and other miRNA markers. Therefore, larger-size, multi-center and higher-quality studies with a unified criterion for determining the expression of miR-200 family microRNAs are necessary to validate the results in this study.
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###### 

Characteristics of studies included in the meta-analysis.

  Study         Year   Sample size   Country   RNA        HR (OS)   LCI (OS)   UCI (OS)   HR (RFS)   LCI (RFS)   UCI (RFS)   Sample type
  ------------- ------ ------------- --------- ---------- --------- ---------- ---------- ---------- ----------- ----------- ---------------
  Cheng         2010   102           USA       miR-141    1.36      0.45       4.14                                          plasma
  Cheng         2010   156           China     miR-141    3.41      1.36       8.56                                          plasma
  DIAZ          2014   127           Spain     miR-429    0.28      0.05       0.42                                          tumor tissues
  Dong          2016   78            China     miR-429    2.296     1.10       4.52                                          tumor tissues
  Li            2013   110           China     miR-429    2.165     1.015      4.618                                         tumor tissues
  Maierthaler   2016   543           Germany   miR-141    1.105     0.904      1.35       1.085      0.89        1.321       plasma
  Maierthaler   2016   543           Germany   miR-200a   1.227     1.008      1.495      1.2        0.989       1.456       plasma
  Maierthaler   2016   543           Germany   miR-200b   1.208     0.975      1.497      1.143      0.919       1.422       plasma
  Maierthaler   2016   543           Germany   miR-200c   1.152     0.975      1.362      1.1        0.93        1.302       plasma
  Maierthaler   2016   543           Germany   miR-429    1.006     0.845      1.198      1.078      0.91        1.277       plasma
  Roh           2018   109           Korea     miR-200c   2.22      0.79       6.26       1.96       0.77        5.02        tumor tissues
  Toiyama       2014   446           Japan     miR-200c   2.67      1.28       5.67       3.01       1.08        8.39        plasma
  Yu            2014   103           China     miR-200c   1.665     1.13       1.135                                         plasma
  Shelton       2018   108           USA       miR-200b   0.459     0.284      0.74                                          tumor tissues
  Shelton       2018   106           USA       miR-200a   0.444     0.216      0.793                                         tumor tissues

###### 

Methodological quality of studies included in the meta-analysis.

  Study                                                                      Cheng   DIAZ   Dong   Li   Maierthaler   Roh   Toiyama   Yu   Shelton
  -------------------------------------------------------------------------- ------- ------ ------ ---- ------------- ----- --------- ---- ---------
  Representativeness of the exposed cohort                                   ☆       ☆      ☆      ☆    ☆             ☆     ☆         ☆    ☆
  Selection of the non-exposed cohort                                        ☆       ☆      ☆      ☆    ☆             ☆     ☆         ☆    ☆
  Ascertainment of exposure                                                  ☆       ☆      ☆      ☆    ☆             ☆     ☆         ☆    ☆
  Demonstration that outcome of interest was not present at start of study   ☆       ☆      ☆      ☆    ☆             ☆     ☆         ☆    ☆
  Comparability of cohorts on the basis of the design or analysis            ☆☆      ☆      ☆☆     ☆☆   ☆             ☆     ☆☆        ☆    ☆
  Assessment of outcome                                                      ☆       ☆      ☆      ☆    ☆             ☆     ☆         ☆    ☆
  Was follow-up long enough for outcomes to occur                            \-      ☆      \-     ☆    ☆             ☆     \-        \-   ☆
  Adequacy of follow-up of cohorts                                           \-      ☆      \-     ☆    ☆             ☆     \-        ☆    \-
  Stars                                                                      7       8      7      9    8             8     7         8    8

###### 

Results of quantitative analysis

  Subgroup        HR     95% CI      I^2^ (%)   P~H~
  --------------- ------ ----------- ---------- ---------
  OS                                            
  Overall         1.18   0.98-1.43   74.1       \<0.001
  Member type                                   
  miR-141         1.58   0.78-3.19   64.1       0.061
  miR-200a        0.78   0.29-2.09   88.4       0.003
  miR-200b        0.76   0.30-1.79   92.3       \<0.001
  miR-200c        1.59   1.09-2.34   63.3       0.043
  miR-429         1.17   0.60-2.30   79.1       0.002
  Location                                      
  Asia            2.06   1.58-2.68   0          0.71
  Europe          1.11   0.99-1.26   46.8       0.094
  America         0.56   0.33-0.91   40.5       0.186
  Sample type                                   
  Plasma          1.23   1.08-1.41   52.3       0.033
  Tumor tissues   0.92   0.44-1.94   83.9       \<0.001
  RFS                                           
  Overall         1.13   1.04-1.23   0          0.446
  Member type                                   
  miR-200c        1.15   0.98-1.35   59.4       0.085
  Location                                      
  Asia            2.39   1.20-4.77   0          0.549
  Europe          1.12   1.03-1.21   0          0.931
  Sample type                                   
  Plasma          1.12   1.03-1.21   0          0.549
  Tumor tissues   2.39   1.20-4.77   0          0.931
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